Kuros Biosciences Ltd. Logo

Kuros Biosciences Ltd.

KURN | SW

Overview

Corporate Details

ISIN(s):
CH0325814116
LEI:
5299006U5POB2AVTT709
Country:
Switzerland
Address:
Wagisstraße 25, 8952 Schlieren
Sector:
Manufacturing
Industry:
Manufacture of medical and dental instruments and supplies

Description

Kuros Biosciences is a medical technology company that discovers, develops, and delivers innovative biologic technologies for tissue repair and bone regeneration. The company's primary focus is on improving outcomes in spinal fusion surgery to address high rates of failed fusions. Its main product is MagnetOs, a bone graft featuring proprietary NeedleGrip™ surface technology, which is designed to grow bone even in soft tissues for more predictable fusions. Kuros Biosciences supports its products through 'Project Fusion,' a global research program that combines scientific, pre-clinical, and clinical studies. The company operates globally with a commercial and research footprint across three continents and more than 20 markets.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Kuros Biosciences Ltd.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-04 02:00
Board/Management Information
Kuros Biosciences announces changes in the Board of Directors
English 7.4 KB
2025-08-14 02:00
Earnings Release
Kuros Biosciences Reports First Half of 2025 Results
English 22.7 KB
2025-03-11 01:00
Earnings Release
Kuros Biosciences grows sales to CHF 75.6 million for 2024
English 19.2 KB
2025-01-08 07:00
Legal Proceedings Report
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the…
English 13.7 KB
2025-01-07 07:00
Regulatory News Service
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the…
English 13.7 KB
2025-01-07 01:00
M&A Activity
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the…
English 11.8 KB
2024-11-19 07:00
Board/Management Information
Kuros Biosciences Expands into Extremities Markets
English 18.5 KB
2024-11-19 01:00
Board/Management Information
Kuros Biosciences Expands into Extremities Markets
English 16.1 KB
2024-10-10 02:00
Earnings Release
Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow brea…
English 16.3 KB
2024-08-08 07:00
Earnings Release
Kuros Biosciences Reports First Half of 2024 Results
English 37.6 KB
2024-08-08 02:00
Earnings Release
Kuros Biosciences Reports First Half of 2024 Results
English 33.0 KB
2024-06-25 07:00
Regulatory News Service
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 …
English 17.2 KB
2024-06-25 02:00
Regulatory News Service
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 …
English 14.9 KB
2024-04-24 07:00
Earnings Release
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct M…
English 17.0 KB
2024-04-24 02:00
Earnings Release
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct M…
English 14.9 KB

Automate Your Workflow. Get a real-time feed of all Kuros Biosciences Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Kuros Biosciences Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-23 N/A Executive member Sell None 1,264,800.00 CHF
2025-04-17 N/A Executive member Sell None 13,344.49 CHF
2025-03-18 N/A Non-Executive member Buy None 38,200.00 CHF
2024-12-11 N/A Executive member Sell None 4,702,500.00 CHF
2024-11-15 N/A Non-Executive member Buy None 925,210.00 CHF
2024-11-14 N/A Non-Executive member Sell None 592,000.00 CHF
2024-11-12 N/A Executive member Sell None 13,890.86 CHF
2024-09-25 N/A Executive member Sell None 8,226,000.00 CHF
2024-09-25 N/A Non-Executive member Sell None 3,656,000.00 CHF
2024-09-24 N/A Non-Executive member Buy None 223,720.00 CHF

Peer Companies

Company Country Ticker View
Theradiag Logo
Develops IVD tests for biotherapy monitoring in autoimmune diseases and oncology.
France ALTER
TISSUE REGENIX GROUP PLC Logo
Develops regenerative biological products for orthopaedic and dental markets.
United Kingdom TRX
Developing disruptive spinal fixation devices for the vertebral surgery market.
United Kingdom N/A
Ulisse Biomed Logo
Provides a portable platform for rapid point-of-need genetic analysis and diagnostics.
Italy UBM
Viromed Medical Logo
Develops cold plasma tech for infection control, wound care, and air disinfection for healthcare.
Germany VMED
Vitrolife Logo
Global provider of medical devices and genetic testing services for the IVF treatment journey.
Sweden VITR
Xvivo Perfusion Logo
Develops ex-vivo machine perfusion systems to improve organ viability for transplantation.
Sweden XVIVO
Ypsomed Holding AG Logo
Develops injection systems for self-medication, partnering with pharma and biotech firms.
Switzerland YPSN